Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mln-0415. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB known ✓ | O14920 | 1/20 | 0.43 |
| ▸ | ICOSLG | O75144 | 11/20 | 0.59 |
| ▸ | ICOS | Q9Y6W8 | 11/20 | 0.59 |
| ▸ | CHUK | O15111 | 15/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | IKBKG | Q9Y6K9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mln-0415 SCHEMBL13270227 | 1.00 | ICOSLG (0.59) | ICOSLGICOSCHUKMEN1IKBKB | |
| Mln-0415 SCHEMBL12619680 | 1.00 | ICOSLG (0.59) | ICOSLGICOSCHUKMEN1IKBKB | |
| Mln-0415 SCHEMBL3805703 | 1.00 | ICOSLG (0.59) | ICOSLGICOSCHUKMEN1IKBKB | |
| Mln-0415 SCHEMBL12619648 | 1.00 | ICOSLG (0.59) | ICOSLGICOSCHUKMEN1IKBKB | |
| Mln-0415 SCHEMBL1798964 | 1.00 | ICOSLG (0.59) | ICOSLGICOSCHUKMEN1IKBKB | |
| Mln-0415 SCHEMBL30489865 | 1.00 | ICOSLG (0.59) | ICOSLGICOSCHUKMEN1IKBKB | |
| Mln-0415 SCHEMBL3809102 | 0.99 | ICOSLG (0.58) | ICOSLGICOSCHUKMEN1IKBKB | |
| Mln-0415 SCHEMBL3809130 | 0.97 | ICOSLG (0.56) | ICOSLGICOSCHUKMEN1IKBKB | |
| Mln-0415 SCHEMBL3812928 | 0.97 | ICOSLG (0.56) | ICOSLGICOSCHUKMEN1IKBKB | |
| Mln-0415 SCHEMBL3812933 | 0.97 | ICOSLG (0.56) | ICOSLGICOSCHUKMEN1IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082652-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2025-03-13 | — | — | US | claimed |
| WO-2023131576-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2023-07-13 | — | — | WO | claimed |
| EP-4209213-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | Universität zu Köln (DE) | 2023-07-12 | — | — | EP | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20250345206-A1 | APPARATUS AND METHODS FOR OCULAR INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-12350261-B2 | Methods and devices for the treatment of ocular diseases in human subjects | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250186253-A1 | DEVICES AND METHODS FOR ADJUSTING THE INSERTION DEPTH OF A NEEDLE FOR MEDICAMENT DELIVERY | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-06-12 | — | — | US | disclosed |
| EP-4566672-A2 | METHODS FOR THE TREATMENT OF OCULAR DISEASE IN HUMAN SUBJECTS | Clearside Biomedical Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| EP-3554435-B1 | SYSTEMS FOR DELIVERING DRUGS TO RETINAL TISSUE | CLEARSIDE BIOMEDICAL INC (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-2206713-A1 | Beta-carbolines useful for treating inflammatory disease | Millennium Pharmaceuticals, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| EP-1735311-B1 | BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE | MILLENNIUM PHARM INC (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090137579-A1 | Mesylate salt of an IKK inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090131422-A1 | Salts of an IKK inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131422-A1 | Salts of an IKK inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131422-A1 | Salts of an IKK inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2009054965-A1 | SALTS OF N- (6-CHLORO-9H-PYRIDO [3,4-B] IND0L-8-YL) -4- [2- (2, 6-DIMETHYL-4-MORPHOLINYL) -2-0X0E THYL] -6, 6-DIMETHYL-MORPHOLINECARBOXAMIDE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009054965-A1 | SALTS OF N- (6-CHLORO-9H-PYRIDO [3,4-B] IND0L-8-YL) -4- [2- (2, 6-DIMETHYL-4-MORPHOLINYL) -2-0X0E THYL] -6, 6-DIMETHYL-MORPHOLINECARBOXAMIDE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009054970-A1 | MESYLATE SALT OF AN IKK INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | IKBKB 2559/4885ICOSLG 3525/4885ICOS 2773/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | IKBKB 3122/4885ICOSLG 4640/4885ICOS 4631/4885 |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | IKBKB 3122/4885ICOSLG 4640/4885ICOS 4631/4885 |
| US-20090137579-A1 | Mesylate salt of an IKK inhibitor | IKBKB, NFKBIA, IKBKE | IKBKB 1/4885ICOSLG 2133/4885ICOS 1396/4885 |
| US-20090131422-A1 | Salts of an IKK inhibitor | NFKBIA, IKBKB, IKBKE | IKBKB 2/4885ICOSLG 4120/4885ICOS 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.